MS
79
2
VMC
65
2
PFE
21
-2
AEE
58
7
IFF
53
5
NTAP
64
3
MMM
44
2
EQIX
65
3
PM
56
6
COST
66
6
VTR
50
3
HRB
59
-7
EQT
54
3
PNC
67
3
CHD
48
3
MAC
62
4
BF.B
25
-3
ADBE
45
-2
SYK
64
2
MA
67
3
MS
79
2
VMC
65
2
PFE
21
-2
AEE
58
7
IFF
53
5
NTAP
64
3
MMM
44
2
EQIX
65
3
PM
56
6
COST
66
6
VTR
50
3
HRB
59
-7
EQT
54
3
PNC
67
3
CHD
48
3
MAC
62
4
BF.B
25
-3
ADBE
45
-2
SYK
64
2
MA
67
3
Financhill
Back

Apellis Pharmaceuticals Quote, Financials, Valuation and Earnings

Yours Free! Top SIX AI Dividend Stocks Right Now

NO CREDIT CARD REQUIRED!
Buy
51

APLS
Apellis Pharmaceuticals

Last Price:
29.96
Seasonality Move:
22.1%

7 Day Trial

ALL ACCESS PASS

$ 7

U.S. Government Report Alert Tuesday

Discover the Secret Loophole

Apellis Pharmaceuticals Price Quote

$29.96
-0.06 (4.25%)
(Updated: November 9, 2024 at 5:12 AM ET)

Apellis Pharmaceuticals Key Stats

Buy
51
Apellis Pharmaceuticals (APLS) is a Buy
Day range:
$28.51 - $30.14
52-week range:
$24.34 - $73.80
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
5.17
P/B ratio:
15.75%
Volume:
2.5M
Avg. volume:
3.4M
1-year change:
-36.11%
Market cap:
$3.7B
Revenue:
$396.6M
EPS:
$-2.03

How Much Does Apellis Pharmaceuticals Make?

Is Apellis Pharmaceuticals Growing As A Company?

Apellis Pharmaceuticals Stock Price Performance

What Is Apellis Pharmaceuticals 52-Week High & Low?

Apellis Pharmaceuticals Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Apellis Pharmaceuticals?

Is Apellis Pharmaceuticals Cash Flow Positive?

  • What Is APLS Cash Flow From Operations?
    Cash flow from operations (TTM) is -$205.1M
  • What Is Apellis Pharmaceuticals’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $149.3M
  • What Is Apellis Pharmaceuticals’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$379K

Apellis Pharmaceuticals Return On Invested Capital

  • Is Management Doing A Good Job?
    APLS return on invested capital is -52.47%
  • What Is Apellis Pharmaceuticals Return On Assets?
    ROA measures how assets are converting to revenues and is -29.46%
  • What Is APLS Return On Equity?
    ROE is a measure of profitability and is -104.65%

Apellis Pharmaceuticals Earnings Date & Stock Price

Apellis Pharmaceuticals Competitors

Apellis Pharmaceuticals Dividend Yield

Apellis Pharmaceuticals Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -71.42%
Revenue: 78.29% -1.5%

Analyst Recommendations

Buy Recommendations: 11
Hold Recommendations: 6
Sell Recommendations: 0
Price Target: 46.79
Upside from Last Price: 55.86%

Major Shareholders

  • How many APLS shares are owned by institutional investors?
    192.1M APLS shares are owned by institutional investors
  • How many APLS shares are owned by insiders?
    3.8M APLS shares are owned by insiders